Effects of H1 antihistamines on animal models of QTc prolongation

Drug Safety

Volumn 21, Issue SUPPL. 1, 1999, Pages 39-44

  Gras, Jordi ^a   Llenas, Jesús ^a  

^a Almirall Prodesfarma ^*  (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CAREBASTINE; CYTOCHROME P450; EBASTINE; FEXOFENADINE; HISTAMINE H1 RECEPTOR ANTAGONIST; KETOCONAZOLE; TERFENADINE;

ANIMAL MODEL; CONFERENCE PAPER; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG SCREENING; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FEMALE; GUINEA PIG; HEART ARRHYTHMIA; HEART REPOLARIZATION; INTRACORONARY INFUSION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PREDICTION; PRIORITY JOURNAL; QT INTERVAL; TORSADE DES POINTES; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; ELECTROCARDIOGRAPHY; LONG QT SYNDROME; MOUSE; PATHOPHYSIOLOGY; REVIEW;

ANIMALS; DOGS; ELECTROCARDIOGRAPHY; GUINEA PIGS; HISTAMINE H1 ANTAGONISTS; LONG QT SYNDROME; MICE;

EID: 0033457982     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199921001-00006     Document Type: Conference Paper

References (30)

1. Sorkin EM, Heel RC. Terfenadine: a review of its pharmacodynamic properties and therapeutic efficacy. Drugs 1985; 29: 34-56
2. Countant JE, Westmark PA, Nardella PA, et al. Determination of terfenadine and terfenadine acid metabolite in plasma using solid-phase extraction and high-performance liquid chromatography with fluorescence detection. J Chromatogr 1991; 570: 139-48
3. Yun CH, Okerholm RA, Guengerich FP. Oxidation of the antihistaminic drug terfenadine in human liver microsomes: role of cytochrome P-450 3A(4) in N-dealkylation and C-hydroxylation. Drug Metab Dispos 1993; 21: 403-9
4. Monahan BP, Ferguson CL, Killeavy ES, et al. Torsades de pointes occurring in association with terfenadine use. JAMA 1990; 264: 2788-90
5. Nightingale SL. Warnings issued on nonsedating antihistamines terfenadine and astemizole. JAMA 1992; 268: 705
6. Honig PK, Woosley RL, Zamani K, et al. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 1992; 52 (3): 231-8
7. Honig PK, Wortham DC, Zamani K, et al. Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences. JAMA 1993; 269 (12): 1513-8
8. Napolitano C, Priori SG, Schwartz PJ. Torsade de pointes. Mechanisms and management. Drugs 1994; 47: 51-65
9. Berul CI, Morad M. Regulation of potassium channels by nonsedating antihistamines. Circulation 1995; 91 (8): 2220-5
10. 1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine. Circ Res 1995; 76 (1): 110-9
11. Lacerda AE, Roy M-L, Lewis EW, et al. Interactions of the nonsedating antihistamine loratadine with Kv 1.5-type potassium channel cloned from human heart. Mol Pharmacol 1997; 52: 314-22
12. Crumb Jr W, Wible B, Arnold DJ, et al. Blockade of multiple human cardiac potassium currents by the antihistamine terfenadine: possible mechanisms for terfenadine-associated cardiotoxicity. Mol Pharmacol 1995; 47: 181-90
13. Lang DG, Wang CM, Wenger TL. Terfenadine alters action potentials in isolated canine Purkinje fibers more than acrivastine. J Cardiovasc Pharmacol 1993; 22: 438-42
14. Adamantidis MM, Lacroix DL, Caron JF, et al. Electrophysiological and arrhythmogenic effects of the histamine type I-receptor antagonist astemizole on rabbit Purkinje fibers: clinical relevance. J Cardiovasc Pharmacol 1995; 26: 319-27
15. Weissenburger J, Davy J-M, Chézalviel F. Experimental models of torsades de pointes. Fund Clin Pharmacol 1993; 7: 29-38
16. Carlsson L, Almgren O, Duker G. QTU-prolongation and torsades de pointes induced by putative class III antiarrhythmic agents in the rabbit: etiology and interventions. J Cardiovasc Pharmacol 1990; 16: 276-85
17. Weissenburger J, Davy J-M, Chézalviel F, et al. Arrhythmogenic activities of antiarrhythmic drugs in conscious hypokalemic dogs with atrioventricular block: comparison between quinidine, lidocaine, flecainide, propranolol and sotalol. J Pharmacol Exp Ther 1991; 259: 871-83
18. Roberts DJ, Llenas J. Some observations on the cardiotoxic and drug interaction profiles of second generation antihistamines as measured in the guinea-pig [comment]. Arzneimittel Forschung 1996; 46 (8): 832-3
19. 1-antihistamines in a guinea-pig model of arrhythmogenicity. Br J Pharmacol 1996; 119: 187-8
20. c interval in guinea pigs pre-treated with ketoconazole. J Allergy Clin Immunol 1998; 101: S254
21. Gras J, Llenas J, Palacios JM. Ebastine is without effect in a sensitive experimental model for detecting prolongation of the QTc interval. Allergy 1996; 51 Suppl. 31: 188
22. Heel RC. Toxicology and safety studies. In: Levine HB, editor. Ketoconazole in the management of fungal disease. Auckland: ADIS Press, 1982: 74-6
23. Hey JA, del Prado M, Kreutner W, et al. Cardiotoxic and drug interaction profile of the second generation antihistamines ebastine and terfenadine in an experimental animal model of torsade de pointes. Arzneimittel Forschung 1996; 46: 159-64
24. Williams A, Redfern WS, Day A, et al. Prolongation of QTc interval by ketoconazole in conscious guinea-pigs implanted with ECG telemetry transducers. Br J Pharmacol 1996; 119 Suppl: 356P
25. Paserchia LA, Hewett J, Woosley RL. Effects of ketoconazole on QTc. Clin Pharmacol Ther 1994; 55: 146
26. Woosley RL, Chen Y, Freiman JP, et al. Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993; 269: 1532-6
27. + channel cloned from human heart. Mol Pharmacol 1993; 44: 1240-5
28. Crumb Jr WJ, Brown AM. Terfenadine blockade of a potassium current in human atrial myocytes. Circulation 1993; 88: 230
29. 1 receptor antagonists, ebastine and terfenadine, on human Kv 1.5 channels. Eur J Pharmatol 1997; 326: 257-63
30. Wiseman LR, Faulds D. Ebastine: a review of its pharmacological properties and clinical efficacy in the treatment of allergic disorders. Drugs 1996; 51: 260-77